Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis

Mavragani, 2014, Sjogren's syndrome, Annu. Rev. Pathol., 9, 273, 10.1146/annurev-pathol-012513-104728

Zintzaras, 2005, The risk of lymphoma development in autoimmune diseases: a meta-analysis, Arch. Intern. Med., 165, 2337, 10.1001/archinte.165.20.2337

Ioannidis, 2002, Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome, Arthritis Rheum., 46, 741, 10.1002/art.10221

Manoussakis, 2007, Arthritis Rheum., 56, 3977, 10.1002/art.23073

Theander, 2011, Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome, Ann. Rheum. Dis., 70, 1363, 10.1136/ard.2010.144782

Tapinos, 1999, Lymphoma development in Sjogren's syndrome: novel p53 mutations, Arthritis Rheum., 42, 1466, 10.1002/1529-0131(199907)42:7<1466::AID-ANR21>3.0.CO;2-L

Pisa, 1991, High frequency of t(14;18) translocation in salivary gland lymphomas from Sjogren's syndrome patients, J. Exp. Med., 174, 1245, 10.1084/jem.174.5.1245

Nezos, 2014, B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome, J. Autoimmun., 51, 89, 10.1016/j.jaut.2013.04.005

Nocturne, 2013, Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome, Blood, 122, 4068, 10.1182/blood-2013-05-503383

Papageorgiou, 2015, A B-cell activating factor receptor (BAFF-R) His159Tyr mutation in Sjogren's Syndrome related lymphoproliferation, Arthritis Rheumatol, 10.1002/art.39231

Gottenberg, 2006, Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome, Proc. Natl. Acad. Sci. U. S. A., 103, 2770, 10.1073/pnas.0510837103

Vakaloglou, 2011, Activation of the type I interferon pathway in primary Sjogren's syndrome: an update, Curr. Opin. Rheumatol., 23, 459, 10.1097/BOR.0b013e328349fd30

Brkic, 2013, Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression, Ann. Rheum. Dis., 72, 728, 10.1136/annrheumdis-2012-201381

Mavragani, 2010, Activation of the type I interferon pathway in primary Sjogren's syndrome, J. Autoimmun., 35, 225, 10.1016/j.jaut.2010.06.012

Hjelmervik, 2005, Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects, Arthritis Rheum., 52, 1534, 10.1002/art.21006

Emamian, 2009, Peripheral blood gene expression profiling in Sjogren's syndrome, Genes Immun., 10, 285, 10.1038/gene.2009.20

Mavragani, 2007, Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept, Arthritis Rheum., 56, 3995, 10.1002/art.23062

Wildenberg, 2008, Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells, Eur. J. Immunol., 38, 2024, 10.1002/eji.200738008

Hall, 2012, Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases, Proc. Natl. Acad. Sci. U. S. A., 109, 17609, 10.1073/pnas.1209724109

Hertzog, 2011, Systems biology of interferon responses, J. Interferon Cytokine Res. Official J. Int. Soc. Interferon Cytokine Res., 31, 5, 10.1089/jir.2010.0126

Ogawa, 2002, Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome, Arthritis Rheum., 46, 2730, 10.1002/art.10577

Ronnblom, 2013, The interferon signature in autoimmune diseases, Curr. Opin. Rheumatol., 25, 248, 10.1097/BOR.0b013e32835c7e32

Cha, 2004, A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse, Scand. J. Immunol., 60, 552, 10.1111/j.0300-9475.2004.01508.x

Nguyen, 2013, The interferon-signature of Sjogren's syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases, Front. Immunol., 4, 142, 10.3389/fimmu.2013.00142

Pollard, 2013, Interferon-gamma and systemic autoimmunity, Discov. Med., 16, 123

Billiau, 2009, Interferon-gamma: a historical perspective, Cytokine Growth Factor Rev., 20, 97, 10.1016/j.cytogfr.2009.02.004

Hu, 2009, Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases, Immunity, 31, 539, 10.1016/j.immuni.2009.09.002

Hall, 2015, Molecular subsetting of interferon pathways in Sjogren's syndrome, Arthritis Rheumatol., 10.1002/art.39204

Mavragani, 2014, Sjogren syndrome, CMAJ, 186, E579, 10.1503/cmaj.122037

Wakamatsu, 2007, DNA microarray analysis of labial salivary glands of patients with Sjogren's syndrome, Ann. Rheum. Dis., 66, 844, 10.1136/ard.2006.063370

Vitali, 2002, Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group, Ann. Rheum. Dis., 61, 554, 10.1136/ard.61.6.554

Hua, 2006, Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies, Arthritis Rheum., 54, 1906, 10.1002/art.21890

Kirou, 2004, Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus, Arthritis Rheum., 50, 3958, 10.1002/art.20798

Maria, 2013, MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome, Ann. Rheum. Dis., 73, 1052, 10.1136/annrheumdis-2012-202552

Kumar-Sinha, 2002, Molecular cross-talk between the TRAIL and interferon signaling pathways, J. Biol. Chem., 277, 575, 10.1074/jbc.M107795200

Porta, 2005, Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively, Oncogene, 24, 605, 10.1038/sj.onc.1208204

Strandberg, 2008, Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies, J. Clin. Immunol., 28, 220, 10.1007/s10875-007-9157-0

Jauharoh, 2012, SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production, Biochem. Biophys. Res. Commun., 417, 582, 10.1016/j.bbrc.2011.12.010

Mariette, 2003, The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome, Ann. Rheum. Dis., 62, 168, 10.1136/ard.62.2.168

Ittah, 2006, B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome, Arthritis Res. Ther., 8, R51, 10.1186/ar1912

Lavie, 2008, B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome, Scand. J. Immunol., 67, 185, 10.1111/j.1365-3083.2007.02049.x

Kirou, 2007, Activation of type I interferon in systemic lupus erythematosus, Expert Rev. Clin. Immunol., 3, 579, 10.1586/1744666X.3.4.579

Mavragani, 2013, Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations, Front. Immunol., 4, 238, 10.3389/fimmu.2013.00238

Dastmalchi, 2008, A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies, Ann. Rheum. Dis., 67, 1670, 10.1136/ard.2007.077974

Markowitz, 2014, A phase I trial of bortezomib and interferon-alpha-2b in metastatic melanoma, J. Immunother., 37, 55, 10.1097/CJI.0000000000000009

Thyrell, 2002, Mechanisms of Interferon-alpha induced apoptosis in malignant cells, Oncogene, 21, 1251, 10.1038/sj.onc.1205179

Kirou, 2000, Induction of Fas ligand-mediated apoptosis by interferon-alpha, Clin. Immunol., 95, 218, 10.1006/clim.2000.4866

Sacre, 2012, Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus, Arthritis Res. Ther., 14, R155, 10.1186/ar3895

Manoussakis, 1996, Antimalarials in Sjogren's syndrome–the Greek experience, Lupus, 5, S28, 10.1177/096120339600500107

Carubbi, 2015, A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjogren's syndrome, Lupus, 24, 315, 10.1177/0961203314554251

Willeke, 2009, Interferon-gamma is increased in patients with primary Sjogren's syndrome and Raynaud's phenomenon, Semin. Arthritis Rheum., 39, 197, 10.1016/j.semarthrit.2008.04.002

Mitsias, 2002, The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome, Clin. Exp. Immunol., 128, 562, 10.1046/j.1365-2249.2002.01869.x

Riedel, 2001, CD4+ Th1-cells predominate in low-grade B-cell lymphoma of gastric mucosa-associated lymphoid tissue (MALT type), Scand. J. Gastroenterol., 36, 1198, 10.1080/00365520152584842

Hauer, 1997, Analysis of TH1 and TH2 cytokine production in low grade B cell gastric MALT-type lymphomas stimulated in vitro with Helicobacter pylori, J. Clin. Pathol., 50, 957, 10.1136/jcp.50.11.957

Rusakiewicz, 2013, NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome, Sci. Transl. Med., 5, 195ra96, 10.1126/scitranslmed.3005727

Yang, 2014, Interferon-gamma-producing B cells induce the formation of gastric lymphoid follicles after Helicobacter suis infection, Mucosal Immunol., 8, 279, 10.1038/mi.2014.66

Kubo-Murai, 2008, IRAK-4-dependent degradation of IRAK-1 is a negative feedback signal for TLR-mediated NF-kappaB activation, J. Biochem., 143, 295, 10.1093/jb/mvm234